SODIUM PUMP INHIBITORS IN CARDIOVASCULAR CONTROL

越来越多的证据表明，洋地黄样因子(EDLF)可能起作用 在心血管疾病发病机制中的重要作用 (高血压、充血性心力衰竭、急性心肌梗死) 通过抑制钠泵活动的能力。引起了极大的关注 被付给了这些因素之一，内源性哇巴因；然而，一个 地高辛样免疫反应因子此前也被发现 有助于心肌缺血时心律失常的发生。目标 本项目的主要内容是阐明各种钠泵的作用 血液中的抑制物，特别是地高辛样免疫反应性EDLF 压力调节。 在过去的一年里，已经对仪表犬进行了研究 通过生理盐水输注来扩大其血浆容量。增加了 通过这一过程诱发的血浆和尿液EDLF与 心肌收缩能力、尿钠排泄增加，以及 血压的可变性升高。动物的前处理 使用抗地高辛抗体可预防或减弱这些影响。 钠泵抑制剂对血管张力和血管钠的影响 对大鼠主动脉和狗股动脉的泵活动进行了研究。 体外培养。与哇巴因的效果相比，EDLF从 中华大蟾毒对钠泵的直接抑制作用 导致快速和持续的血管收缩。与哇巴因不同， 这个EDLF独立于交感神经系统发挥作用。 这些研究对于理解地球的起源具有重要意义。 高血压与新药理的发展 心血管疾病的干预。

Evidence has accumulated that digitalis-like factors (EDLF) may play an important role in the pathogenesis of cardiovascular disease (hypertension, congestive heart failure, acute myocardial infarction) via their ability to inhibit sodium pump activity. Much attention has been paid to one of these factors, an endogenous ouabain; however, a digoxin-like immunoreactive factor has also been found previously to contribute to arrythmogenesis in myocardial ischemia. The objectives of this project are to clarify the role of various sodium pump inhibitors, especially the digoxin-like immunoreactive EDLF, in blood pressure regulation. Over the past year, studies have been performed with instrumented dogs whose plasma volume was expanded via saline infusion. Increases in plasma and urinary EDLF evoked by this procedure were associated with increases in cardiac contractility, urinary sodium excretion, and variable increases in blood pressure. Pretreatment of the animals with an antidigoxin antibody prevented or attenuated these effects. Effects of sodium pump inhibitors on vascular tone and vascular sodium pump activity in rat aortas and dog femoral arteries were studied in vitro. Compared with the effects of ouabain, EDLF obtained from the venom of Bufo marinus toad caused direct inhibition of sodium pump resulting in rapid and sustained vasoconstriction. Unlike ouabain, this EDLF acted independently of the sympathetic nervous system. These studies have implications for understanding of the origins of hypertension and for the development of new pharmacological interventions in cardiovascular disorders.